Molecular Imaging Corporation Schedules Conference Call to Discuss Third Quarter Fiscal Results; Call Scheduled for Tuesday May 18, 2004 4:30 PM EST.Business Editors/Health/Medical Writers BIOWIRE2K SAN DIEGO--(BUSINESS WIRE)--May 12, 2004 Molecular Imaging Corporation ("MLRI" or the "Company") (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB: MLRI), a leading provider of Molecular Imaging Services to healthcare entities in the U.S., today announced that it has scheduled a conference call for 1:30 PST PST Paroxysmal supraventricular tachycardia, see there , 4:30 EST EST electroshock therapy. EST abbr. electroshock therapy , Tuesday, May 18th, 2004 to discuss financial and operating results for the fiscal 3rd quarter 2004. For those wishing to participate, the conference call is accessible by telephone at (866) 253-5757. Ask the operator to be connected to the Molecular Imaging Corp conference call, access code 467006. The call will be recorded and available for listening until 8/18/04 by dialing (888) 266-2081, access code 467006. About Molecular Imaging Corporation Molecular Imaging Corporation is a leading national service provider of Positron Emission Tomography positron emission tomography: see PET scan. positron emission tomography (PET) Imaging technique used in diagnosis and biomedical research. ("PET") diagnostic imaging services. PET is a 3-Dimensional Full Body molecular imaging procedure used to diagnose stage and assess treatment outcomes for many cancers, cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease and neurological disorders This is a list of major and frequently observed neurological disorders (e.g. Alzheimer's disease), symptoms (e.g.back pain), signs (e.g. aphasia) and syndromes (e.g. Aicardi syndrome). . The Company operates both mobile and permanent (fixed) PET imaging technologies for hospitals, diagnostic imaging centers and physician group practices offices across the U.S. The Company's clinical web site, www.PETadvances.com addresses questions about the various cancers and how molecular imaging can assist and benefit physicians and their patients. The Company's commercial web site, (www.molecularimagingcorp.com) addresses questions about our commercial services and investor relations Investor relations The process by which the corporation communicates with its investors. . Certain statements contained in this press release are "forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. " within the meaning of applicable federal securities laws, including, without limitation, anything relating or referring to future financial results and plans for future business development activities, and are thus prospective. Forward-looking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified based on current expectations. Such risks and uncertainties include, without limitation, the risks and uncertainties set forth from time to time in reports filed by the company with the Securities and Exchange Commission. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward the forward-looking statements contained herein. The companies undertake no obligation to publicly release statements made to reflect events or circumstances after the date hereof. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion